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CHAPTER I 
 
                     INTRODUCTION: 
   
“Nature is nowhere accustomed more openly to display her secret 
mysteries than in cases where she shows traces of her workings apart from 
the beaten path; nor is there any better way to advance the proper practice 
of medicine than to give our minds to discovery of the usual law of Nature 
by careful investigation of cases of rarer forms of disease. For it has been 
found, in almost all things, that what they contain of useful or applicable is 
hardly perceived unless we are deprived of them, or they become deranged 
in some way”.  [William Harvey: 1657, in a letter to a colleague]. 
 
This quotation may seem of strange origin and vintage to start this thesis. However, it 
embodies the very basis upon which my career eventually settled. In a rallying call that is 
anathema to Medical Students, Harvey applauds the study of “the rarer forms of disease”, 
something that most Medical School teaching tends to avoid!  It is serendipitous that 
Harvey also used the concept of “workings apart from the beaten path” thus predating the 
use of the concept of a biochemical pathway by several centuries!  I have indeed used 
this quotation in many lectures to emphasize the point that a curious mind should be open 
to all sorts of new and unexpected wonders, that rare disorders can indeed inform us 
about many more mundane problems and that this applies particularly to areas of 
Medicine where almost everything still waits to be discovered. 
Many of the reports in my CV represent either the first known case of some disorder 
or a very early case in which we had done some special studies. I make no apologies for 
having reported upon so many rare disorders nor for including them in this anthology. In 
each case, I believed that they offered something new to the emerging science of 
metabolism. In addition, when a rare disorder is “discovered” through a few case reports, 
it always turns out that additional cases have been lurking in other clinics around the 
world and also that, once recognized, even more additional cases are found. 
Repeatedly in this collection, it can be seen how the initial reports of a condition, 
often little more than clinical observations, have led over the years into far more in depth 
understanding of physiology, enzymology, organelle pathophysiology, gene identification 
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and an understanding of gene function.  In the future, I expect to see many new advances 
in gene therapy. 
 
References derived from my CV are given as the numbers in the CV and highlighted in 
grey.  Other references are included in the text identified by the name of the first author. 
 
My background. 
I arrived in University College, Dundee in 1950 to study Medicine.  At that time it was 
still thought that humans had 48 chromosomes, [the correct number, 46 was only 
identified in 1956, the year I graduated].  I will recall the excitement when vitamin B12 and 
the the “mycin family of antibiotics were discovered.   Many of my teachers had still been 
trained in the pre-antibiotic era and much of our teaching was coloured by pre- and 
immediate post-war medical practice.  I was sure that I wanted to become a country GP 
similar to AJ Cronin, one of my boyhood heroes.  By the time I graduated, however, I had 
become fascinated by the unusual, the rare and challenging cases – an interest fostered 
by the late Dr Walter Strauss in Arbroath Infirmary. 
During my post-graduate training, this bent became entrenched and I mutated into 
becoming a University Professor, whose specialty was in the most rare and esoteric of 
areas – namely the nascent field of Clinical Genetics and especially Inborn Errors of 
Metabolism [IEM].  This might have seemed like an unlikely direction to follow especially 
since I recall that the sum total of lectures in physiological biochemistry we received in 
UCD had numbered only five!  When my conversion started, there were no laboratories 
that specialized in this field, no analysers available to detect quantitative abnormalities 
plasma amino acids or other metabolites, there were only a handful of disorders that no 
physician really expected ever to encounter and there were no specialists in this field.  
The standard method for detecting most metabolites was by paper or thin layer 
chromatography. It was a triumph just to establish a real diagnosis. 
In the course of my registarships in Dundee Royal Infirmary, it became apparent to 
me and my professors that I would be best suited to a career in some branch of 
academia.  At that time, in order to achieve that, it was almost essential to obtain a “BTA” 
status [BTA – Been To America!] since there was still hardly any opportunity to do 
research in post-war UK.  In 1963, I elected to try for a Fellowship in renal disease in the 
US, but Professor John Henderson [Department of Child Health] arranged a fellowship for 
me to work in Denver, Colorado with Dr Donough O’Brien in his new microchemistry 
laboratory.  After my rudimentary basic lectures in biochemistry this prospect frightened 
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me so much that I armed myself with a slip of paper on which the formula for each amino 
acid was displayed; it stayed in my wallet for many years! 
Once in Colorado, I became intimately familiar with all the workings of an amino acid 
analyser, [I could repair them and keep them running and even build one from 
components], and all of the exciting new diseases that such a machine could surely 
detect. When I first started, a complete run on this machine took 21 hours to complete.  
By the end of my fellowship we had reduced this time to six hours and with better 
resolution.  Such analysers were just becoming more available in the US, designed for 
use in centres specializing in the nascent field of Biochemical Genetics.  One technical 
achievement I did make was able to develop a method that separates the free amino 
acids from all peptides in urine and this is the technical article I have chosen for this 
treatise. [See reference 3 in Chapter XII]. 
At the end of my two-year fellowship it transpired that there would be no amino acid 
analyser available to me if I returned to Scotland and I thus reluctantly decided to stay in 
the US at least for a few years.  I was appointed to a new position in the University of 
Oregon Medical School with the mandate to develop a clinical centre for the diagnosis, 
investigation, treatment and research into inborn errors of metabolism.  To start with, this 
whole program was funded by a grant for $30,000 from the March of Dimes without which 
both I and my programme would never have been able to grow and to flourish. 
 
Biochemical Genetics as a specialty gets started. 
The first group to formalize the field of metabolic diseases was the Society for the 
Study of Inborn Errors of Metabolism [SSIEM] in the UK; it was only founded in 1963.  Dr 
O’Brien was one of the originators of the specialty and also founding father of the Society 
for Inherited Metabolic Disorders [SIMD] in the US, but even this American counterpart to 
the SSIEM was only founded in 1987; I too was one of the founding members and was 
the treasurer for 25 years. Other Societies have followed with groups in Canada, South 
America, Europe, India, China, Japan and elsewhere. 
It will be clear that my career in this specialty spans the entire academic history of 
the specialty.  As would be expected, much of my bibliography relates to clinical detection 
and evaluation.  It has been exciting to watch the evolution of this specialty from a kind of 
“Gee-Whiz” mentality into one of the most academic specialties in the whole of Medicine; 
my colleagues have been the pioneers in the application of DNA technologies to clinical 
situations, both for diagnostic reasons and also for potential therapies.  I have had the 
great fortune to work all this time with the evolution of this specialty into a field that has 
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specialists in most countries and covers over 1000 disorders each with many genetic 
variants.  A web site dedicated to sharing information about problems and questions in 
this field [Metab-L] has contributors from over 100 countries.  The standard reference on 
the subject is a five-volume textbook, now only available online – The Online Metabolic 
and Molecular Bases of Inherited Disease edited by Scriver.  Biochemical Genetics is 
now a full-fledged specialty in its own right.  Several major reference textbooks are shown 
at the end of this chapter. 
 
My role in Newborn Screening. 
From the outset, I worked not only at the University but also with the state newborn 
screening laboratory where the world’s first routine screening for phenylketonuria [PKU] 
was started early in 1961.  This added another dimension to my interests in that I was 
integral to many of the decisions and developments that were occurring in newborn 
screening.  The Oregon newborn screening  programme was one of the pioneers in this 
field and it has maintained its preeminent position ever since.  We became known for our 
work with aminoacidopathies but soon we were branching out to many of the other 
disorders that were being discovered and unraveled.  Our programme introduced many 
novel tests, maple syrup urine disease, muscular dystrophy [See Reference 94 Chapter 
CC]. We also screened 100,000 infants for alpha-1-antitrypsin deficiency and detected 22 
cases giving a far higher incidence than was thought at the time; as far as I know, no 
other screening programme has ever repeated our experience and none has reported on 
the outcome of such cases after 20 years [80]. 
We were the first place in the world to start screening for congenital adrenal 
hyperplasia which we did because of a very high incidence of this disorder in Alaskan 
Natives.   We also included screening for maternal PKU in the state programme of 
prenatal testing for syphilis; we tested 330,000 women and found 15 cases with variably 
elevated blood levels of phenylalanine. Most had been born before the advent of routine 
newborn screening.  This was a startling number that showed that not all patients with 
hyperphenylalaninaemia were grossly delayed and cemented the idea that many milder 
cases of this disorder were present in the community.  The multiparous women who had 
previously had children that were developmentally delayed. 
My clinic nurse, Judi Tuerck RN, developed the seminal idea that newborn screening 
must not be considered only a laboratory programme but as a complete system that 
included not only the initial collection and handling of specimens, the total activity in the 
screening laboratory, the follow-up and treatment and also the essential evaluation of the 
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success of all these components [69]. Thus was born the concept of Newborn Screening 
Practice and its essential role in quality assurance inthese programmes.  This was 
surprisingly a hard concept for many since most screening programmes at the time were 
based entirely in state laboratories that had little or no contact with any clinical follow up.  
We also developed the first regional screening centre in the US eventually growing to 
include seven other states.  At one stage it spanned from Delaware in the east coast of 
the US to Khatmandhu in the Far East, an area close to that of Western Europe but with a 
population of only about 8-10 million. 
My greatest success in this field was to get screening for neonatal hypothyroidism 
started in the US, we became only the second centre in the world to do this [38,43]; it is 
now mandatory in most screening programmes around the world. 
 
38.  LaFranchi, S., Buist, N.R.M., Murphey, W.H., Larsen, P.R., Foley, T.P., Jr.:  
Transient neonatal hypothyroidism detected by newborn screening program.  Pediatr. 
60:538-541, 1977. 
43.  LaFranchi, S.,Murphey, W.H., Foley, T.P., Larsen, P.R., Buist, N.R.M.:  Neonatal 
hypothyroidism detected by the Northwest regional screening program.  Pediatr. 63:180-
191, 1979. 
69.  Tuerck, J.M., Buist, N.R.M., Skeels, M.R., Miyahira, R.S., Beach, P.G.:  
Computerized surveillance of errors in newborn screening practice.  Amer. J. Public 
Health 77:1528-1531, 1987. 
80.  Wall, M., Moe, E., Eisenberg, J., Powers, M., Buist, N.R.M. and Buist, A.S.:  Long 
term follow-up of a cohort of children with alpha-1-antitrypsin deficiency.  J. Ped.116: 248-
251,1990. 
 
 
My Clinic. 
The clinic that I established at the University eventually became the largest of its kind 
in the US.  This was partly because we had our own laboratory and because I decided 
from the start that we should include all referrals for potential metabolic disorders and see 
people of all ages.  Soon I was holding clinics throughout Oregon and then in Idaho, 
Montana and Nevada as well as some in Alaska.  Once again the area and the population 
were about the same size as that covered by the screening programme. I would travel up 
to 1000 miles for such clinics and some patients would still have to travel 300 miles just to 
see me in consultation – a true outreach system! 
By the end of my tenure at the University, over 150 different metabolic disorders 
were represented in the clinic roster.  Some were the only known cases either in the US 
or even the whole world.  The oldest patients were both 90 years old, one with hereditary 
fructosaemia and the other with gyrate atrophy of the retina [a defect of ornithine 
metabolism]. 
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Many specialist’s careers tend to concentrate on one or only a few areas of special 
interest during their career.  I however, being responsible for all metabolic diseases, was 
able to explore a wide variety of disorders.  Such huge diversity led inevitably to endless 
potential topics for research much of which could be conducted in my own laboratory.  
With passing years and more experts available, it became increasingly advantageous to 
share patients and samples with people who had more in depth experience in specific 
problems.  These days, when only a handful of cases of a disorder are known in the 
whole world, there is now usually someone who has made it their career interest and with 
whom it is best to collaborate for optimal results.  This evolution is reflected throughout 
my CV in which over 40 different inborn  
 
errors are represented and in which many studies are shared with other centres.  To 
some extent, I viewed myself as a clinical pimp whose job it was to detect interesting 
cases and then get them studied elsewhere in more depth than we could ever hope to 
provide in Oregon. 
 
My Laboratory. 
Much of the credit for the growth and success of our programme must be attributed 
to Nancy Kennaway D. Phil. who was in charge of the laboratory and who all too 
frequently had to rein in my enthusiasm to study the newest and latest problem we had 
uncovered in one of the clinics. The mainstay of our testing was a batch of simple 
screening tests [4] accompanied by one-dimensional paper chromatography of blood or 
urine.  This  “Metabolic Screening” yielded huge dividends in diagnosis and the detection 
of unusual metabolic patterns. The laboratory had a great deal of freedom [before the 
advent of layers of administration] to be able to develop and explore any area that we 
thought to be of interest or value in the field.  Dr Kennaway’s fastidious attention to detail 
gave to laboratory a world-wide reputation [and often saved my bacon as well!].  It was 
the combined association of the newborn screening, the clinics and particularly my 
Metabolic Laboratory that helped to make this centre so successful in so many areas. 
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